Compare drug alternatives

Haegarda® Alternatives

Haegarda®(C1 esterase inhibitor)
Ruconest®(C1 esterase inhibitor)
Prescription Only
Haegarda is a synthetic version of a blood protein that regulates swelling in the body. Individuals with Hereditary Angioedema (HAE) lack sufficient levels of this protein,...
Prescription Only
Ruconest is a synthetic version of the naturally occurring c1 esterase inhibitor protein in the bloodstream, which plays a crucial role in regulating swelling in the body....
Dosage & Administration
Administration
Subcutaneous . Learn more.
Intravenous. Learn more.
Dosing
Administer 60 International Units per kg body weight twice weekly (every 3 or 4 days).. Learn more.
Weight <84 kg: 50 U per kg. Weight ≥84 kg: 4200 U (2 vials).. Learn more.
Latin Shorthand
Administer 60 IU/kg BW BID (q3-4d).. Learn more.
Weight <84 kg: 50 U/kg. Weight ≥84 kg: 4200 U (2 vials).. Learn more.
Financial Assistance
Out-Of-Pocket Costs With Copay Card
Annual Cap
Assistance Expiration
Generics
No lower-cost generic available
No lower-cost generic available
Physician Advisory
Adverse Reactions
Adverse reactions occurring in more than 4% of subjects treated with HAEGARDA were injection site reactions, hypersensitivity, nasopharyngitis and dizziness.. Learn more.
The serious adverse reaction reported in clinical trials was anaphylactic reaction. The common adverse reactions (≥ 2%) reported in clinical trials were headache, nausea, and diarrhea.. Learn more.
Mechanism of Actions (MoA)
Drugs used in Hereditary Angioedema. Learn more.
Drugs used in Hereditary Angioedema. Learn more.
Special Populations
1. Is it safe to use HAEGARDA during pregnancy?

There are no prospective clinical data from HAEGARDA use in pregnant women. However, limited retrospective data suggest that C1-INH treatment during pregnancy did not lead to adverse events. The estimated background risk of birth defects and miscarriage in the general U.S. population is 2-4% and 15-20%, respectively.

2. What is known about HAEGARDA use during lactation?

There is no information available about the presence of HAEGARDA in human milk, its impact on breastfed infants, or its effects on milk production. The decision to breastfeed should consider the benefits of breastfeeding and the mother's clinical need for HAEGARDA, while also evaluating potential adverse effects on the breastfed infant.

3. Has HAEGARDA been tested in pediatric patients?

Yes, the safety and effectiveness of HAEGARDA were evaluated in a subgroup of patients aged 8 to <17 years in clinical trials, and the results were consistent with overall study results.

4. Is HAEGARDA suitable for use in geriatric patients?

Clinical studies of HAEGARDA did not include sufficient numbers of subjects aged 65 and over to determine if they respond differently from younger subjects. However, reported clinical experience has not identified differences in responses between the elderly and younger patients. Dosing for elderly patients should be cautious and typically start at the lower end of the dosing range, considering factors like decreased hepatic, renal, or cardiac function, and concomitant diseases or other drug therapies.

1. Is RUCONEST safe to use during pregnancy?

There are no adequate and well-controlled studies of RUCONEST in pregnant women. Limited postmarketing data suggest no adverse effects in pregnant women treated with RUCONEST. A retrospective case collection study involving 14 pregnant women who received RUCONEST did not report adverse events related to RUCONEST treatment, and all women delivered healthy babies. However, the data's ability to definitively establish absence of risk is limited due to the study's small sample size and non-randomized design.

2. What do we know about RUCONEST use during lactation?

There is no available data on the presence of RUCONEST in human milk, its effects on breastfed infants, or its impact on milk production. When considering the use of RUCONEST, the developmental and health benefits of breastfeeding should be balanced with the mother's clinical need, while also assessing potential adverse effects on the breastfed child from RUCONEST or the maternal condition.

3. Has RUCONEST been tested in pediatric patients?

Yes, the safety and efficacy of RUCONEST were evaluated in 17 adolescent patients aged 13-17 years who were treated for HAE attacks. Some adverse reactions were observed in these patients, with the most common being abdominal pain, headache, and oropharyngeal pain. However, no serious adverse reactions were reported.

4. Is RUCONEST suitable for use in geriatric patients?

Clinical studies of RUCONEST included seven patients older than 65 years, but the number of patients in this age group was insufficient to determine whether they respond differently from younger patients.